Janine Ziermann to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Janine Ziermann has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.375
-
Burchert A, Saussele S, Eigendorff E, M?ller MC, Sohlbach K, Inselmann S, Sch?tz C, Metzelder SK, Ziermann J, Kostrewa P, Hoffmann J, Hehlmann R, Neubauer A, Hochhaus A. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015 Jun; 29(6):1331-5.
Score: 0.128
-
Schmidt M, Rinke J, Sch?fer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014 Dec; 28(12):2292-9.
Score: 0.124
-
Frietsch JJ, Kastner C, Grunewald TG, Schweigel H, Nollau P, Ziermann J, Clement JH, La Ros?e P, Hochhaus A, Butt E. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget. 2014 Jul 30; 5(14):5257-71.
Score: 0.123